Monograph Details
|
|
Musculoskeletal Disorders
> Bone disorders
|
|
FORTEO |
| Manufacturer |
|
Lilly, Eli and Company |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Hormone (human parathyroid hormone, recombinant). |
| Generic Name |
|
Teriparatide (recombinant) 250micrograms/mL; soln for SC inj; contains m-cresol. |
| Indications |
|
Postmenopausal osteoporosis in women who are at high risk for fracture. To increase bone mass in men with primary or hypogonadal osteoporosis who are at high risk for fracture. |
| Children |
|
Not recommended. |
| Adults |
|
20 micrograms SC once daily into thigh or abdominal wall; may treat for up to 2 years. |
| Contraindications |
|
Increased baseline risk for osteosarcoma (eg, Paget's disease of bone, unexplained increased alkaline phosphatase, open epiphyses, prior skeletal radiation therapy). Bone metastases. History of skeletal malignancies. Metabolic bone disease. Hypercalcemia or risk thereof (eg, hyperparathyroidism). Pregnancy (Cat.C). Nursing mothers. |
| Precautions |
|
Urolithiasis. Hypercalciuria. Hepatic, renal, or cardiac disease. |
| Interactions |
|
Caution with digoxin (teriparatide-induced hypercalcemia increases risk of toxicity). |
| Adverse Reactions |
|
Dizziness, leg cramps; transient orthostatic hypotension, hypercalcemia, hyperuricemia, inj site reactions. |
| How Supplied |
|
Multidose Pen (3mL)—1 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
